Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management of thyroid eye disease.

Luigi Bartalena1, Claudio Marcocci, Laura Tanda

  • 1Department of Endocrinology, University of Insubria, Ospedale di Circolo, Viale Borri, 57, 21100 Varese, Italy. l.bartalena@libero.it

European Journal of Nuclear Medicine and Molecular Imaging
|August 23, 2002
PubMed
Summary

Thyroid eye disease (TED), an extrathyroidal manifestation of Graves

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome near-haploidization in CDC73-wildtype parathyroid tumors.

Scientific reports·2026
Same author

Mutational patterns in a large cohort of parathyroid carcinomas.

Journal of endocrinological investigation·2026
Same author

Use of total calcium in hypoparathyroidism: a pragmatic approach but with limitations.

European journal of endocrinology·2025
Same author

Consensus statement on vitamin D role in metabolic health.

Metabolism: clinical and experimental·2025
Same author

Revised European Society of Endocrinology Clinical Practice Guideline: Treatment of Chronic Hypoparathyroidism in Adults.

European journal of endocrinology·2025
Same author

Role of MEN1 mutations on postoperative outcomes of patients with multiple endocrine neoplasia type 1-related primary hyperparathyroidism: a single center experience.

Journal of endocrinological investigation·2025

Area of Science:

  • Endocrinology and Ophthalmology

Background:

  • Thyroid eye disease (TED) is the most common extrathyroidal manifestation of Graves' disease.
  • While often mild, 3%-5% of TED cases are severe and progressive.

Purpose of the Study:

  • To outline current management strategies for thyroid eye disease based on severity and activity.
  • To highlight the importance of risk factor modification and coordinated care.
  • To introduce potential novel therapeutic agents.

Main Methods:

  • Review of current treatment modalities for non-severe and severe TED.
  • Emphasis on assessing disease severity and activity for treatment selection.
  • Discussion of risk factor management, including smoking cessation.
  • Consideration of combined hyperthyroidism and TED treatment approaches.

Main Results:

  • Non-severe TED management involves supportive measures like eye ointments and sunglasses.
  • Severe TED necessitates aggressive medical (glucocorticoids, radiotherapy) or surgical (orbital decompression) interventions.
  • Treatment choice is guided by TED severity and activity assessment.
  • Risk factor control, particularly smoking cessation, significantly improves outcomes.
  • Coordinated management of hyperthyroidism and TED is crucial.

Conclusions:

  • Effective management of TED hinges on accurate assessment of disease severity and activity.
  • Aggressive treatment and risk factor modification are vital for severe cases.
  • Emerging therapies like somatostatin analogues and cytokine antagonists show promise but require further validation.

Related Experiment Videos